title: Predictors of anti-vascular endothelial growth factor treatment responses in macular edema following central vein occlusion.
authors.affiliation: Department of Ophthalmology, Shanghai First People's Hospital, School of Medicine, Shanghai JiaoTong University, Shanghai 200080, China.
authors.forename: Peirong
authors.initials: P
authors.lastname: Huang
authors.affiliation: Shanghai Key Laboratory of Fundus Disease, Eye Research Institute of Shanghai Jiao Tong University, Shanghai 200080, China.
authors.forename: Zhengyu
authors.initials: Z
authors.lastname: Song
authors.affiliation: Department of Ophthalmology, Shanghai First People's Hospital, School of Medicine, Shanghai JiaoTong University, Shanghai 200080, China. Email: xdsun@sjtu.edu.cn.
authors.forename: Xiaodong
authors.initials: X
authors.lastname: Sun
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D052157:Aptamers, Nucleotide / Q000627:therapeutic use; D000068258:Bevacizumab; D006801:Humans; D008269:Macular Edema / Q000188:drug therapy*; D000069579:Ranibizumab; D040262:Receptors, Vascular Endothelial Growth Factor / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D012170:Retinal Vein Occlusion / Q000188:drug therapy*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014792:Visual Acuity / Q000187:drug effects
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide; D011993:Recombinant Fusion Proteins; D042461:Vascular Endothelial Growth Factor A; C533178:aflibercept; C495058:pegaptanib; D000068258:Bevacizumab; D040262:Receptors, Vascular Endothelial Growth Factor; D000069579:Ranibizumab